Novel BRD2::NUTM1 Fusion in NUT Carcinoma With Exceptional Response to Chemotherapy: A Case Report

Sarah J. Wu, MD, PhD; Justin J. Kim; Yeying Huang, BS; R. Taylor Durall, BS; Simone Becker, RN; Stephanie Canty, CNP, MSN; Stefania Molinaro, BS; Evan Pisick, MD; Geoffrey I. Shapiro, MD, PhD; Christopher A. French, MD; Jia Luo, MD

JTO Clinical and Research Reports (Jan 2024)

Novel BRD2::NUTM1 Fusion in NUT Carcinoma With Exceptional Response to Chemotherapy: A Case Report

Sarah J. Wu, MD, PhD,
Justin J. Kim,
Yeying Huang, BS,
R. Taylor Durall, BS,
Simone Becker, RN,
Stephanie Canty, CNP, MSN,
Stefania Molinaro, BS,
Evan Pisick, MD,
Geoffrey I. Shapiro, MD, PhD,
Christopher A. French, MD,
Jia Luo, MD

Affiliations

Sarah J. Wu, MD, PhD: Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts
Justin J. Kim: Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Biology, Colby College, Waterville, Massachusetts
Yeying Huang, BS: Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts
R. Taylor Durall, BS: Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts
Simone Becker, RN: Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
Stephanie Canty, CNP, MSN: Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
Stefania Molinaro, BS: Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
Evan Pisick, MD: City of Hope Chicago, Zion, Illinois
Geoffrey I. Shapiro, MD, PhD: Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
Christopher A. French, MD: Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts
Jia Luo, MD: Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts; Department of Medicine, Brigham and Women’s Hospital, Boston, Massachusetts; Corresponding author. Address for correspondence: Jia Luo, MD, Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue LC4116, Boston, MA 02215.

Journal volume & issue: Vol. 5, no. 1
p. 100625

Abstract

Read online

We present the first known case of a patient with BRD2::NUTM1-driven NUT carcinoma. A 59-year-old woman presented with poorly differentiated squamous cell lung cancer metastatic to the pleura. Eventually, a positive NUT immunohistochemistry, NUT fluorescence in situ hybridization, and RNA next-generation sequencing with a BRD2::NUTM1 fusion led to the diagnosis of NUT carcinoma. She received multiple lines of chemotherapy with response and is still alive at 2 years postdiagnosis. This report expands on the known fusions in NUT carcinoma and highlights potential differences in patient prognosis on the basis of gene fusion partners.

Published in JTO Clinical and Research Reports

ISSN: 2666-3643 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Website: https://www.journals.elsevier.com/jto-clinical-and-research-reports/

About the journal

Abstract

Keywords